Jolanta Kamińska, Maciej Głyda, Joanna Sobiak, Maria Chrzanowska A C 40 l] 35 /hm30 g× 25 μ [h20 4 - C0 15 U AA 10 PM 5 0 40 l] 35 /hm30 g× 25 μ [h20 4 - C0 15 U AA 10 PM 5 0 r = –0.022 p = 0.886 r = –0.097 p = 0.534 p 0.886 0.007 0.194 < 0.001 < 0.001 < 0.001 0.534 0.029 0.095 < 0.001 < 0.001 < 0.001 B 1000 l] 900 /m800 ×h700 [gμ600 -4h500 C0400 AU300 AG200 P M100 0 D 1000 l] 900 /m800 ×h700 [gμ600 -4h500 C0400 AU300 AG200 P M100 0 0 r 0.068 –0.494 0.289 –0.668 –0.702 –0.589 –0.078 0.494 –0.312 0.756 0.691 0.625 p 0.763 0.019 0.193 < 0.001 < 0.001 0.004 0.730 0.020 0.158 < 0.001 < 0.001 0.002 r –0.178 –0.460 0.043 –0.860 –0.849 –0.848 –0.127 0.208 –0.152 0.810 0.762 0.816 r = –0.783 p < 0.001 r = –0.782 p < 0.001 p 0.440 0.036 0.854 < 0.001 < 0.001 < 0.001 0.584 0.365 0.510 < 0.001 < 0.001 < 0.001 0 20 40 60 80 100 Creatinine clearance [ml/min] 120 140 0 20 40 60 80 100 Creatinine clearance [ml/min] 120 140 0 1 2 3 4 Serum creatinine [mg/dl] 5 6 1 2 3 4 Serum creatinine [mg/dl] 5 6 Figure 2. Correlation between creatinine clearance (A-B) or serum creatinine (C-D) and mycophenolic acid (MPA) or mycophenolic acid glucuronide (MPAG) area under the curve (AUC) in renal transplant recipients Table IV. Spearman’s rank correlation between creatinine clearance or serum creatinine and PK parameters of MPA and MPAG in patients treated with Tac or CsA All (n = 43) Tac (n = 22) CsA (n = 21) Creatinine clearance [ml/min] MPA MPAG MPA MPAG AUC0-4 h [μg × h/ml] C0 [μg/ml] Cmax [μg/ml] AUC0-4 h [μg × h/ml] C0 [μg/ml] Cmax [μg/ml] Serum creatinine [mg/dl] AUC0-4 h [μg × h/ml] C0 [μg/ml] Cmax [μg/ml] AUC0-4 h [μg × h/ml] C0 [μg/ml] Cmax [μg/ml] r –0.023 –0.406 0.202 –0.783 –0.793 –0.724 –0.098 0.333 –0.258 0.782 0.739 0.713 PK – pharmacokinetic, MPA – mycophenolic acid, MPAG – 7-O-mycophenolic acid glucuronide, Tac – tacrolimus, CsA – cyclosporine, AUC – area under the concentration-time curve, C0 – pre-dose concentration, Cmax – maximum concentration 92 Arch Med Sci 1, February / 2012